ASCO 2025 Kidney Cancer

Viewing 1-20 of 23 articles

ASCO 2025: STARLITE-1: Phase 1b/2 Study of Combination 177Lu Girentuximab plus Cabozantinib and Nivolumab in Treatment Naive Patients with Advanced Clear Cell RCC

ASCO 2025: A Phase 1/2 First in Human Study of ADI-270, an Armored Allogeneic Anti-CD70 Chimeric Antigen Receptor γδ T Cell Therapy, in Relapsed or Refractory (R/R) Clear Cell Renal Cell Carcinoma

ASCO 2025: Neoadjuvant Lenvatinib plus Pembrolizumab for Resectable Clear-Cell Renal Cell Carcinoma (PELUR): A Prospective Phase 2 Study

ASCO 2025: STARLITE 2: Phase 2 Study of Nivolumab plus 177lutetium-Labeled Anti–carbonic Anhydrase IX (CAIX) Monoclonal Antibody Girentuximab (177Lu-Girentuximab) in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

ASCO 2025: Efficacy and Safety of Second-Line Cabozantinib +/ Atezolizumab for Patients with Advanced Renal Cell Carcinoma After Progression on Immuno-Oncology Combinations: Subgroup Analysis of CONTACT-03

ASCO 2025: Discussion: From Established Therapies to Emerging Innovations in Renal Cell Carcinoma: Checkpoints, Oxygen, and T Cells

ASCO 2025: Discussion: Guts, Blood and Tumor: The Search for Kidney Cancer Biomarkers Continues

ASCO 2025: ALLO-316 in Advanced Clear Cell Renal Cell Carcinoma: Updated Results from the Phase 1 TRAVERSE Study

ASCO 2025: Combination Casdatifan plus Cabozantinib Expansion Cohort of Phase 1 ARC-20 Study in Previously Treated Patients with Clear Cell Renal Cell Carcinoma

ASCO 2025: Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitor Belzutifan in Von Hippel-Lindau (VHL) Disease–associated Neoplasms: 5-Year Follow-up of the Phase 2 LITESPARK-004 Study

ASCO 2025: Nivolumab plus Ipilimumab vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma: Final Analysis from the Phase 3 CheckMate 214 Trial

ASCO 2025: Exploratory Analysis from NEOAVAX, a Neoadjuvant Trial of Avelumab/axitinib in Patients with Localized Renal Cell Carcinoma Who Are at High Risk of Relapse After Nephrectomy

ASCO 2025: Biomarkers in Kidney Cancer: Are We There Yet?

ASCO 2025: Targeting HIF-2α: A New Frontier in Renal Cell Cancer Therapy

ASCO 2025: An Integrative Analysis of Circulating and Tumor Microenvironment Determinants of Patient Response in the Checkmate 9ER Trial of Nivolumab and Cabozantinib in Advanced Renal Cell Carcinoma

ASCO 2025: Functional Imaging in Renal Cell Carcinoma: Enhancing Diagnosis and Treatment Strategies

ASCO 2025: Ipilimumab/nivolumab Versus Standard of Care in Non-Clear Cell Renal Cancer: Results of the SUNNIFORECAST Trial and Potential Role of the CPS Score and Tumor Nephrectomy

ASCO 2025: RADICAL/Alliance A031801: A Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced RCC with Osseous Metastases

ASCO 2025: Zanzalintinib + Nivolumab ± Relatlimab in Patients with Previously Untreated Clear Cell RCC: Results from an Expansion Cohort of the Phase 1b STELLAR-002 Study

ASCO 2025: Ipilimumab and Nivolumab in Patients with Metastatic Clear Cell RCC Treated on the Phase 3 PDIGREE (Alliance A031704) Trial: Results from Step 1 Analysis

1
2